



Myriad Pharmaceuticals, Inc. to Host Initial Public Conference Call On July 1, 2009

SALT LAKE CITY, June 29, 2009 (GLOBE NEWSWIRE) -- [Myriad Pharmaceuticals](#), Inc. (Nasdaq:MYRXV) today announced that it will hold a live webcast on Wednesday, July 1, 2009 at 10:00 AM EDT. Adrian Hobden, Ph.D., the Company's President and Chief Executive Officer will provide an overview of the Company's corporate strategy and pipeline of novel small molecule drug candidates to treat severe medical conditions, including cancer and HIV infection.

[Myriad Pharmaceuticals](#) is a wholly owned subsidiary of Myriad Genetics, Inc. (Nasdaq:MYGN). [Myriad Pharmaceuticals](#) expects to complete its spin-off from Myriad Genetics, Inc. on June 30, 2009 and be an independent company on July 1, 2009. [Myriad Pharmaceuticals](#)' common stock has been approved for listing on the NASDAQ Global Market and is expected to begin trading on July 1, 2009 under the symbol "MYRX". Until the Company begins trading on the NASDAQ Global Market, [Myriad Pharmaceuticals](#) is trading under the symbol "MYRXV", denoting its "when-issued" trading status.

Conference Call Information

To access the webcast and slide presentation, a link can be found on [Myriad Pharmaceuticals](#)' website www.myriadpharma.com. An audio of the webcast can also be accessed by dialing 877-741-4244 (domestic) or 719-325-4825 (international). A replay of the webcast will be available on the Company's website, www.myriadpharma.com, in the Investor Relations section after 12:00 PM EDT on July 1, 2009.

About [Myriad Pharmaceuticals](#), Inc.

[Myriad Pharmaceuticals](#), Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing novel small molecule drugs that address severe medical conditions, including cancer and HIV infection. Our pipeline includes clinical and pre-clinical product candidates with distinct mechanisms of action and novel chemical structures that have the potential to be first-in-class and/or best-in-class therapeutics. For more information visit www.myriadpharma.com.

The [Myriad Pharmaceuticals](#), Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=6327>

Forward-Looking Statements

This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the Company's live webcast on Wednesday, July 1st at 10:00 AM EST; the overview of the Company's corporate strategy and pipeline of novel small molecule drug candidates to treat severe medical conditions, including cancer and HIV infection; the expected timing of events relating to the spin-off of the Company from Myriad Genetics, Inc., and the Company's expectation to begin trading on July 1, 2009 under the symbol "MYRX." These "forward-looking statements" are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks and uncertainties include, but are not limited to: the risk that we may be unable to further identify, develop and achieve commercial success for new products and technologies; the risk that we may be unable to discover drugs that are safer and more efficacious than our competitors; the risk that we may be unable to develop and maintain manufacturing capabilities for our products; the possibility of delays in the research and development necessary to select drug development candidates and delays in clinical trials; the risk that clinical trials may not result in marketable products; the risk that we may be unable to successfully finance and secure regulatory approval of and market our drug candidates, or that clinical trials will not be completed on the timelines we have estimated; uncertainties about our ability to obtain new corporate collaborations and acquire new technologies on satisfactory terms, if at all; the development of competing products and services; the risk that we may be unable to protect our proprietary technologies; the risk of patent-infringement claims; risks of new, changing and competitive technologies and regulations in the United States and internationally; and other factors discussed under the heading "Risk Factors" contained in our Form 10 which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in this press release is as of the date of the release, and [Myriad Pharmaceuticals](#) undertakes no duty to update this information unless required by law.

CONTACT: Myriad Pharmaceuticals, Inc.
Patrick M. Burke, Ph.D, V.P. Corporate and Business
Development
801-214-7822
Fax: 801-214-7992
investor.relations@myriadpharma.com

MacDougall Biomedical Communications
Douglas MacDougall
Chris Erdman
781-235-3060